NCT06915831 Type 1 Diabetes and Obstructive Sleep Apnea
| NCT ID | NCT06915831 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Sleep Apnea, Obstructive |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-11-10 |
| Primary Completion | 2029-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-11-10 with a primary completion date of 2029-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to investigate the role of sleep apnea in glycemic dysregulation in adults with Type 1 diabetes.
Eligibility Criteria
Inclusion Criteria: * Age: 18 to 50 years old * Type 1 Diabetes on insulin pump therapy and using a CGM device with an GMI (glucose management indicator) between 5.5 and 8.5% with hemoglobin in the normal range at screening * OSA by home sleep apnea test Exclusion Criteria: * Regular and adherent CPAP use per clinical guidelines * Requiring oxygen or advanced positive airway pressure modalities during sleep * Having a 'fall-asleep' or 'near miss' accident in the past 6-months * Shift work * Severe hypoglycemia (≥1 episode in the past 3 months or diagnosis of hypoglycemic unawareness) * ≥1 trip to emergency room for poor glucose management in the past 6 months * Proliferative retinopathy * Fasting triglycerides \>400mg/dL, * Liver transaminases \>2 times upper limit of normal, * Renal transplantation or serum creatinine \>1.5 mg/dL * Anemia (hemoglobin \<13.0g/dL in men or \<11.6g/dL in women) * Acute coronary syndrome or stroke past 6 months * Severe hypertension (blood pressure\>180/105 mmHg) * Any other significant health condition: unstable angina, heart failure requiring hospitalization in the past 6 months, significant heart block or arrhythmias, NYHA Class\>2, pulmonary disease with dependence on oxygen or daily use of bronchodilators, active or chronic infection, thyroid disease and other endocrine disorders (e.g. Cushing syndrome, acromegaly) * Recent major surgery * Major psychiatric disorder * Subjects will also be excluded if taking medications that can confound metabolic assessments including systemic glucocorticoids, antipsychotics, thiazide diuretics, beta-blockers, daily use of aminophylline or theophylline, or use of any immunosuppressant. * Currently pregnant or trying to get pregnant or nursing * Smoking, alcohol or illegal drug abuse
Contact & Investigator
Esra Tasali, MD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06915831 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Sleep Apnea, Obstructive. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06915831 currently recruiting?
Yes, NCT06915831 is actively recruiting participants. Contact the research team at etasali@bsd.uchicago.edu for enrollment information.
Where is the NCT06915831 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06915831 clinical trial?
NCT06915831 is sponsored by University of Chicago. The principal investigator is Esra Tasali, MD at University of Chicago. The trial plans to enroll 40 participants.